You may delay, but time will not. Beta cells lost are never found again: a case for timely initiation of basal insulin in type 2 diabetes
Postgrad Med. 2024 Mar 11. doi: 10.1080/00325481.2024.2328511. Online ahead of print.ABSTRACTSince its first use just over a century ago, insulin treatment has evolved dramatically, such that the molecules are physiologic in nature, and treatment can now closely resemble the natural hormone response over 24 hours. Newer, longer-acting basal insulin analogs have provided insulin therapies with improved characteristics and, therefore, ease of use, and can readily be incorporated as part of routine treatment for type 2 diabetes (T2D), but evidence suggests that insulin remains underused in people with T2D. We review the barri...
Source: Postgraduate Medicine - March 11, 2024 Category: Internal Medicine Authors: Susan Renda Jeffrey Freeman Source Type: research
Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting
CONCLUSIONS: Primary care providers are ideally placed to identify at-risk individuals, implement evidence-based interventions to prevent the development of fibrosis and cirrhosis, and effectively manage comorbidities. Equipping primary care providers with the necessary knowledge and tools to effectively manage MASLD/MASH may help to improve patient outcomes and reduce the burden of liver disease.PMID:38465573 | DOI:10.1080/00325481.2024.2325332 (Source: Postgraduate Medicine)
Source: Postgraduate Medicine - March 11, 2024 Category: Internal Medicine Authors: Alina M Allen Michael Charlton Kenneth Cusi Stephen A Harrison Kris V Kowdley Mazen Noureddin Jay H Shubrook Source Type: research
You may delay, but time will not. Beta cells lost are never found again: a case for timely initiation of basal insulin in type 2 diabetes
Postgrad Med. 2024 Mar 11. doi: 10.1080/00325481.2024.2328511. Online ahead of print.ABSTRACTSince its first use just over a century ago, insulin treatment has evolved dramatically, such that the molecules are physiologic in nature, and treatment can now closely resemble the natural hormone response over 24 hours. Newer, longer-acting basal insulin analogs have provided insulin therapies with improved characteristics and, therefore, ease of use, and can readily be incorporated as part of routine treatment for type 2 diabetes (T2D), but evidence suggests that insulin remains underused in people with T2D. We review the barri...
Source: Postgraduate Medicine - March 11, 2024 Category: Internal Medicine Authors: Susan Renda Jeffrey Freeman Source Type: research
Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting
CONCLUSIONS: Primary care providers are ideally placed to identify at-risk individuals, implement evidence-based interventions to prevent the development of fibrosis and cirrhosis, and effectively manage comorbidities. Equipping primary care providers with the necessary knowledge and tools to effectively manage MASLD/MASH may help to improve patient outcomes and reduce the burden of liver disease.PMID:38465573 | DOI:10.1080/00325481.2024.2325332 (Source: Postgraduate Medicine)
Source: Postgraduate Medicine - March 11, 2024 Category: Internal Medicine Authors: Alina M Allen Michael Charlton Kenneth Cusi Stephen A Harrison Kris V Kowdley Mazen Noureddin Jay H Shubrook Source Type: research
You may delay, but time will not. Beta cells lost are never found again: a case for timely initiation of basal insulin in type 2 diabetes
Postgrad Med. 2024 Mar 11. doi: 10.1080/00325481.2024.2328511. Online ahead of print.ABSTRACTSince its first use just over a century ago, insulin treatment has evolved dramatically, such that the molecules are physiologic in nature, and treatment can now closely resemble the natural hormone response over 24 hours. Newer, longer-acting basal insulin analogs have provided insulin therapies with improved characteristics and, therefore, ease of use, and can readily be incorporated as part of routine treatment for type 2 diabetes (T2D), but evidence suggests that insulin remains underused in people with T2D. We review the barri...
Source: Postgraduate Medicine - March 11, 2024 Category: Internal Medicine Authors: Susan Renda Jeffrey Freeman Source Type: research
Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting
CONCLUSIONS: Primary care providers are ideally placed to identify at-risk individuals, implement evidence-based interventions to prevent the development of fibrosis and cirrhosis, and effectively manage comorbidities. Equipping primary care providers with the necessary knowledge and tools to effectively manage MASLD/MASH may help to improve patient outcomes and reduce the burden of liver disease.PMID:38465573 | DOI:10.1080/00325481.2024.2325332 (Source: Postgraduate Medicine)
Source: Postgraduate Medicine - March 11, 2024 Category: Internal Medicine Authors: Alina M Allen Michael Charlton Kenneth Cusi Stephen A Harrison Kris V Kowdley Mazen Noureddin Jay H Shubrook Source Type: research
You may delay, but time will not. Beta cells lost are never found again: a case for timely initiation of basal insulin in type 2 diabetes
Postgrad Med. 2024 Mar 11. doi: 10.1080/00325481.2024.2328511. Online ahead of print.ABSTRACTSince its first use just over a century ago, insulin treatment has evolved dramatically, such that the molecules are physiologic in nature, and treatment can now closely resemble the natural hormone response over 24 hours. Newer, longer-acting basal insulin analogs have provided insulin therapies with improved characteristics and, therefore, ease of use, and can readily be incorporated as part of routine treatment for type 2 diabetes (T2D), but evidence suggests that insulin remains underused in people with T2D. We review the barri...
Source: Postgraduate Medicine - March 11, 2024 Category: Internal Medicine Authors: Susan Renda Jeffrey Freeman Source Type: research
Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting
CONCLUSIONS: Primary care providers are ideally placed to identify at-risk individuals, implement evidence-based interventions to prevent the development of fibrosis and cirrhosis, and effectively manage comorbidities. Equipping primary care providers with the necessary knowledge and tools to effectively manage MASLD/MASH may help to improve patient outcomes and reduce the burden of liver disease.PMID:38465573 | DOI:10.1080/00325481.2024.2325332 (Source: Postgraduate Medicine)
Source: Postgraduate Medicine - March 11, 2024 Category: Internal Medicine Authors: Alina M Allen Michael Charlton Kenneth Cusi Stephen A Harrison Kris V Kowdley Mazen Noureddin Jay H Shubrook Source Type: research
You may delay, but time will not. Beta cells lost are never found again: a case for timely initiation of basal insulin in type 2 diabetes
Postgrad Med. 2024 Mar 11. doi: 10.1080/00325481.2024.2328511. Online ahead of print.ABSTRACTSince its first use just over a century ago, insulin treatment has evolved dramatically, such that the molecules are physiologic in nature, and treatment can now closely resemble the natural hormone response over 24 hours. Newer, longer-acting basal insulin analogs have provided insulin therapies with improved characteristics and, therefore, ease of use, and can readily be incorporated as part of routine treatment for type 2 diabetes (T2D), but evidence suggests that insulin remains underused in people with T2D. We review the barri...
Source: Postgraduate Medicine - March 11, 2024 Category: Internal Medicine Authors: Susan Renda Jeffrey Freeman Source Type: research
Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting
CONCLUSIONS: Primary care providers are ideally placed to identify at-risk individuals, implement evidence-based interventions to prevent the development of fibrosis and cirrhosis, and effectively manage comorbidities. Equipping primary care providers with the necessary knowledge and tools to effectively manage MASLD/MASH may help to improve patient outcomes and reduce the burden of liver disease.PMID:38465573 | DOI:10.1080/00325481.2024.2325332 (Source: Postgraduate Medicine)
Source: Postgraduate Medicine - March 11, 2024 Category: Internal Medicine Authors: Alina M Allen Michael Charlton Kenneth Cusi Stephen A Harrison Kris V Kowdley Mazen Noureddin Jay H Shubrook Source Type: research
You may delay, but time will not. Beta cells lost are never found again: a case for timely initiation of basal insulin in type 2 diabetes
Postgrad Med. 2024 Mar 11. doi: 10.1080/00325481.2024.2328511. Online ahead of print.ABSTRACTSince its first use just over a century ago, insulin treatment has evolved dramatically, such that the molecules are physiologic in nature, and treatment can now closely resemble the natural hormone response over 24 hours. Newer, longer-acting basal insulin analogs have provided insulin therapies with improved characteristics and, therefore, ease of use, and can readily be incorporated as part of routine treatment for type 2 diabetes (T2D), but evidence suggests that insulin remains underused in people with T2D. We review the barri...
Source: Postgraduate Medicine - March 11, 2024 Category: Internal Medicine Authors: Susan Renda Jeffrey Freeman Source Type: research
Prognostic significance of body mass index and serum albumin as the indicators of nutritional status in small cell lung cancer
CONCLUSION: Even though BMI and serum albumin showed no prognostic value in SCLC patients treated with chemotherapy, PS was found to be the most significant prognostic factor in both LD- and ED-SCLC stages.PMID:38456321 | DOI:10.1080/00325481.2024.2328512 (Source: Postgraduate Medicine)
Source: Postgraduate Medicine - March 8, 2024 Category: Internal Medicine Authors: Faruk Tas Ak ın Ozturk Kayhan Erturk Source Type: research
Association between variants in < em > TCF7L2 < /em > , < em > CTRB1/2 < /em > , and < em > GLP-1R < /em > genes and response to therapy with glucagon-like peptide-1 receptor agonists
CONCLUSION: There is no evidence suggesting a role for the variants studied in response to GLP-1 RA therapy in people with T2DM. However, specific demographic and clinical factors may be related to a better response to treatment with these agents.PMID:38453649 | DOI:10.1080/00325481.2024.2328513 (Source: Postgraduate Medicine)
Source: Postgraduate Medicine - March 7, 2024 Category: Internal Medicine Authors: Artemis Kyriakidou Angeliki V Kyriazou Theocharis Koufakis Yiannis Vasilopoulos Iakovos Avramidis Stefanos Baltagiannis Dimitrios G Goulis Kalliopi Kotsa Source Type: research
